Rehlko Expands Power Plus™ Connected-Services Capabilities, Enhancing Value Across Installed Base August 11, 2026 Rehlko Power Plus™ Delivers 24/7 Remote Monitoring, Advanced Diagnostics, and Fleet-Wide Asset Visibility to Critical Power Systems
Smarsh Named to Inc. 5000 for the 19th Consecutive Year August 11, 2026 Smarsh continues to lead the industry with sustained AI-driven innovation and growth
GXP-Storage Expands UK Capacity with Third Restricted-Access Facility at Raunds, Northamptonshire August 11, 2026 The company’s third UK facility adds 95,000+ cubic feet of GxP-compliant, environmentally controlled storage capacity and serves as a consolidation point for regulated materials across the UK, EMEA, and beyond.
Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe August 11, 2026 Transaction highlights Advances Alfasigma’s M&A-led global growth strategy, purposely focused on immunology and gastroenterology. Synergy with Alfasigma’s specialty rheumatology portfolio, adding Nordic Pharma’s rheumatoid arthritis business, including the Nordimet® franchise. Expands footprint by adding Canada and Japan; strengthens presence in Europe, with direct operations in 18 countries, with 265 employees. Adds approximately €190 million in 2025 revenue. Financial terms of the transaction are not disclosed.
AT&T-Led Neutral-Host Network Powers New Connectivity Experience at Davis Wade Stadium August 10, 2026 AT&T customers at Mississippi State University’s Davis Wade Stadium in Starkville are getting a boost in wireless connectivity following the deployment of a new AT&T-led distributed antenna system, or DAS, powered by Airspan’s MobileAccess 6000 Digital platform. Led and owned by AT&T as a neutral-host network, the new DAS is designed to deliver high-capacity, multi-operator [...]
Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile August 10, 2026 Trial met its primary endpoint, with a significantly higher proportion of clinical responders on divesiran (88%) compared to placebo (19%); placebo-adjusted response rate = 69% Both divesiran dose groups showed substantial primary endpoint efficacy; 93.8% response rate at Q6W and 81.3% response rate at Q12W Divesiran was observed to be well tolerated with no new safety findings Phase 3 PV trial evaluating divesiran Q12W vs. placebo anticipated to initiate in 1H’27 Investor conference call and webcast to be held today, August 10, 2026 at 8:00 a.m. ET
Silence Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera August 9, 2026 Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced a conference call and webcast to discuss topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera (PV) scheduled for tomorrow, Monday, August 10, 2026 at 8:00 a.m. EDT. Investor Webcast & Conference Call [...]
Cloudflare Adds AEO Visibility Dashboard to Its AEO Suite, Showing Brands Whether AI Assistants Are Recommending Them August 6, 2026 New AEO Visibility Dashboard gives brand marketers a clear view of how AI assistants are citing, mentioning, and ranking them
AM Best Upgrades Fortegra Insurance Subsidiaries to A (Excellent) August 6, 2026 Rating actions follow completion of the DB Insurance acquisition
Mary Kay’s Pink Changing Lives® Program Turns Purpose Into Measurable Impact for Women Around the World August 6, 2026 More than 4 million women have benefited through nonprofit organizations supported by the program since its launch.